ID   HDBP1_HUMAN             Reviewed;         184 AA.
AC   Q8IV16; Q6P3T2; Q86W15;
DT   05-FEB-2008, integrated into UniProtKB/Swiss-Prot.
DT   07-DEC-2004, sequence version 2.
DT   10-MAY-2017, entry version 116.
DE   RecName: Full=Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1;
DE            Short=GPI-HBP1;
DE            Short=GPI-anchored HDL-binding protein 1;
DE   AltName: Full=High density lipoprotein-binding protein 1;
DE   Flags: Precursor;
GN   Name=GPIHBP1; Synonyms=HBP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Shan Y.X., Yu L.;
RT   "Isolation and characterization of human HBP1 gene.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT PHE-14.
RC   TISSUE=Brain, and PNS;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH APOA5 AND LPL, AND CHARACTERIZATION OF VARIANT
RP   ARG-56.
RX   PubMed=17997385; DOI=10.1016/j.bbalip.2007.10.005;
RA   Gin P., Beigneux A.P., Davies B., Young M.F., Ryan R.O., Bensadoun A.,
RA   Fong L.G., Young S.G.;
RT   "Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to
RT   GPIHBP1 containing a G56R amino acid substitution.";
RL   Biochim. Biophys. Acta 1771:1464-1468(2007).
RN   [5]
RP   REVIEW.
RX   PubMed=21844202; DOI=10.1194/jlr.R018689;
RA   Young S.G., Davies B.S., Voss C.V., Gin P., Weinstein M.M.,
RA   Tontonoz P., Reue K., Bensadoun A., Fong L.G., Beigneux A.P.;
RT   "GPIHBP1, an endothelial cell transporter for lipoprotein lipase.";
RL   J. Lipid Res. 52:1869-1884(2011).
RN   [6]
RP   VARIANT ARG-56.
RX   PubMed=17883852; DOI=10.1186/1476-511X-6-23;
RA   Wang J., Hegele R.A.;
RT   "Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-
RT   anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two
RT   siblings with fasting chylomicronemia (MIM 144650).";
RL   Lipids Health Dis. 6:23-23(2007).
RN   [7]
RP   VARIANT HLPP1D PRO-115, AND CHARACTERIZATION OF VARIANT HLPP1D
RP   PRO-115.
RX   PubMed=19304573; DOI=10.1161/ATVBAHA.109.186577;
RA   Beigneux A.P., Franssen R., Bensadoun A., Gin P., Melford K.,
RA   Peter J., Walzem R.L., Weinstein M.M., Davies B.S.J.,
RA   Kuivenhoven J.A., Kastelein J.J.P., Fong L.G., Dallinga-Thie G.M.,
RA   Young S.G.;
RT   "Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind
RT   lipoprotein lipase.";
RL   Arterioscler. Thromb. Vasc. Biol. 29:956-962(2009).
RN   [8]
RP   VARIANTS HLPP1D SER-65 AND GLY-68, AND CHARACTERIZATION OF VARIANTS
RP   HLPP1D SER-65 AND GLY-68.
RX   PubMed=20026666; DOI=10.1194/jlr.M002717;
RA   Olivecrona G., Ehrenborg E., Semb H., Makoveichuk E., Lindberg A.,
RA   Hayden M.R., Gin P., Davies B.S., Weinstein M.M., Fong L.G.,
RA   Beigneux A.P., Young S.G., Olivecrona T., Hernell O.;
RT   "Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in
RT   familial chylomicronemia.";
RL   J. Lipid Res. 51:1535-1545(2010).
RN   [9]
RP   VARIANTS HLPP1D PHE-89 AND ARG-175, VARIANT PHE-14, CHARACTERIZATION
RP   OF VARIANTS HLPP1D PHE-89 AND ARG-175, AND CHARACTERIZATION OF VARIANT
RP   PHE-14.
RX   PubMed=21816778; DOI=10.1210/jc.2011-1444;
RA   Charriere S., Peretti N., Bernard S., Di Filippo M., Sassolas A.,
RA   Merlin M., Delay M., Debard C., Lefai E., Lachaux A., Moulin P.,
RA   Marcais C.;
RT   "GPIHBP1 C89F neomutation and hydrophobic C-terminal domain G175R
RT   mutation in two pedigrees with severe hyperchylomicronemia.";
RL   J. Clin. Endocrinol. Metab. 96:E1675-E1679(2011).
RN   [10]
RP   VARIANT HLPP1D TYR-68.
RX   PubMed=21314738; DOI=10.1111/j.1365-2796.2011.02361.x;
RA   Coca-Prieto I., Kroupa O., Gonzalez-Santos P., Magne J.,
RA   Olivecrona G., Ehrenborg E., Valdivielso P.;
RT   "Childhood-onset chylomicronaemia with reduced plasma lipoprotein
RT   lipase activity and mass: identification of a novel GPIHBP1
RT   mutation.";
RL   J. Intern. Med. 270:224-228(2011).
RN   [11]
RP   VARIANTS HLPP1D TYR-65; ARG-108; PRO-115 AND PHE-144.
RX   PubMed=22239554; DOI=10.1111/j.1365-2796.2012.02516.x;
RA   Surendran R.P., Visser M.E., Heemelaar S., Wang J., Peter J.,
RA   Defesche J.C., Kuivenhoven J.A., Hosseini M., Peterfy M.,
RA   Kastelein J.J., Johansen C.T., Hegele R.A., Stroes E.S.,
RA   Dallinga-Thie G.M.;
RT   "Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with
RT   severe hypertriglyceridaemia.";
RL   J. Intern. Med. 272:185-196(2012).
RN   [12]
RP   VARIANT PHE-14, VARIANT HLPP1D ARG-68, CHARACTERIZATION OF VARIANT
RP   PHE-14, AND CHARACTERIZATION OF VARIANT HLPP1D ARG-68.
RX   PubMed=23831619; DOI=10.5551/jat.18861;
RA   Yamamoto H., Onishi M., Miyamoto N., Oki R., Ueda H., Ishigami M.,
RA   Hiraoka H., Matsuzawa Y., Kihara S.;
RT   "Novel combined GPIHBP1 mutations in a patient with
RT   hypertriglyceridemia associated with CAD.";
RL   J. Atheroscler. Thromb. 20:777-784(2013).
RN   [13]
RP   CHARACTERIZATION OF VARIANTS HLPP1D SER-65; TYR-65; ARG-68; GLY-68;
RP   TYR-68; PHE-89; ARG-108 AND PRO-115, SUBUNIT, INTERACTION WITH LPL,
RP   AND MUTAGENESIS OF TYR-66; LEU-71; THR-91; LEU-92; ILE-93; GLY-101;
RP   THR-104; THR-105; HIS-106; SER-107; THR-108; TRP-109; GLN-115 AND
RP   VAL-126.
RX   PubMed=25387803; DOI=10.1161/CIRCRESAHA.116.305085;
RA   Beigneux A.P., Fong L.G., Bensadoun A., Davies B.S., Oberer M.,
RA   Gaardsvoll H., Ploug M., Young S.G.;
RT   "GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and
RT   thereby prevent lipoprotein lipase binding.";
RL   Circ. Res. 116:624-632(2015).
RN   [14]
RP   VARIANT HLPP1D ARG-83.
RX   PubMed=27578123; DOI=10.1016/j.jacl.2016.03.009;
RA   Rabacchi C., D'Addato S., Palmisano S., Lucchi T., Bertolini S.,
RA   Calandra S., Tarugi P.;
RT   "Clinical and genetic features of 3 patients with familial
RT   chylomicronemia due to mutations in GPIHBP1 gene.";
RL   J. Clin. Lipidol. 10:915-921(2016).
CC   -!- FUNCTION: Plays a key role in the lipolytic processing of
CC       chylomicrons. Required for the transport of lipoprotein lipase LPL
CC       into the capillary lumen (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Mostly monomer, but also homodimer and homooligomer
CC       (PubMed:25387803). Interacts with high affinity with high-density
CC       lipoprotein (HDL) (By similarity). Only monomer interacts with
CC       lipoprotein lipase (LPL) (PubMed:25387803, PubMed:17997385).
CC       Interacts with chylomicrons and APOA5 (PubMed:17997385).
CC       {ECO:0000250|UniProtKB:Q9D1N2, ECO:0000269|PubMed:17997385,
CC       ECO:0000269|PubMed:25387803}.
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000250|UniProtKB:Q9D1N2}; Lipid-anchor, GPI-anchor
CC       {ECO:0000250|UniProtKB:Q9D1N2}. Basolateral cell membrane
CC       {ECO:0000250|UniProtKB:Q9D1N2}; Lipid-anchor, GPI-anchor
CC       {ECO:0000250|UniProtKB:Q9D1N2}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q9D1N2}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q9D1N2}; Extracellular side
CC       {ECO:0000250|UniProtKB:Q9D1N2}.
CC   -!- PTM: Glycosylation of Asn-78 is critical for cell surface
CC       localization and the binding of chylomicrons and lipoprotein
CC       lipase. {ECO:0000250}.
CC   -!- POLYMORPHISM: The missense variant Arg-56 may be associated with
CC       severe hypertriglyceridemia and chylomicronemia.
CC   -!- DISEASE: Hyperlipoproteinemia 1D (HLPP1D) [MIM:615947]: An
CC       autosomal recessive disorder characterized by
CC       hyperlipoproteinemia, decreased plasma LPL levels in some
CC       patients, high plasma triglyceride levels, and refractory fasting
CC       chylomicronemia. {ECO:0000269|PubMed:19304573,
CC       ECO:0000269|PubMed:20026666, ECO:0000269|PubMed:21314738,
CC       ECO:0000269|PubMed:21816778, ECO:0000269|PubMed:22239554,
CC       ECO:0000269|PubMed:23831619, ECO:0000269|PubMed:25387803,
CC       ECO:0000269|PubMed:27578123}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY245915; AAO86519.1; -; mRNA.
DR   EMBL; CH471162; EAW82276.1; -; Genomic_DNA.
DR   EMBL; BC035810; AAH35810.2; -; mRNA.
DR   EMBL; BC063857; AAH63857.1; -; mRNA.
DR   CCDS; CCDS34954.1; -.
DR   RefSeq; NP_001288701.1; NM_001301772.1.
DR   RefSeq; NP_835466.2; NM_178172.5.
DR   UniGene; Hs.426410; -.
DR   ProteinModelPortal; Q8IV16; -.
DR   IntAct; Q8IV16; 1.
DR   STRING; 9606.ENSP00000329266; -.
DR   iPTMnet; Q8IV16; -.
DR   PhosphoSitePlus; Q8IV16; -.
DR   BioMuta; GPIHBP1; -.
DR   DMDM; 74728020; -.
DR   PaxDb; Q8IV16; -.
DR   PeptideAtlas; Q8IV16; -.
DR   PRIDE; Q8IV16; -.
DR   DNASU; 338328; -.
DR   Ensembl; ENST00000622500; ENSP00000480053; ENSG00000277494.
DR   GeneID; 338328; -.
DR   KEGG; hsa:338328; -.
DR   UCSC; uc033cbs.1; human.
DR   CTD; 338328; -.
DR   DisGeNET; 338328; -.
DR   GeneCards; GPIHBP1; -.
DR   HGNC; HGNC:24945; GPIHBP1.
DR   HPA; HPA066302; -.
DR   MalaCards; GPIHBP1; -.
DR   MIM; 612757; gene.
DR   MIM; 615947; phenotype.
DR   neXtProt; NX_Q8IV16; -.
DR   Orphanet; 411; Hyperlipoproteinemia type 1.
DR   Orphanet; 70470; Hyperlipoproteinemia type 5.
DR   PharmGKB; PA162390135; -.
DR   eggNOG; ENOG410J46G; Eukaryota.
DR   eggNOG; ENOG41116TR; LUCA.
DR   HOGENOM; HOG000112872; -.
DR   InParanoid; Q8IV16; -.
DR   KO; K20001; -.
DR   OrthoDB; EOG091G0UW5; -.
DR   PhylomeDB; Q8IV16; -.
DR   TreeFam; TF338440; -.
DR   Reactome; R-HSA-163125; Post-translational modification: synthesis of GPI-anchored proteins.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   GenomeRNAi; 338328; -.
DR   PRO; PR:Q8IV16; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000182851; -.
DR   CleanEx; HS_GPIHBP1; -.
DR   CleanEx; HS_HBP1; -.
DR   Genevisible; Q8IV16; HS.
DR   GO; GO:0031362; C:anchored component of external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IEA:UniProtKB-KW.
DR   GO; GO:0005622; C:intracellular; IEA:GOC.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0035478; F:chylomicron binding; IDA:BHF-UCL.
DR   GO; GO:0008035; F:high-density lipoprotein particle binding; IEA:Ensembl.
DR   GO; GO:0035473; F:lipase binding; IPI:BHF-UCL.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0071813; F:lipoprotein particle binding; IDA:UniProtKB.
DR   GO; GO:0008320; F:protein transmembrane transporter activity; ISS:BHF-UCL.
DR   GO; GO:0006501; P:C-terminal protein lipidation; TAS:Reactome.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISS:BHF-UCL.
DR   GO; GO:0006886; P:intracellular protein transport; ISS:BHF-UCL.
DR   GO; GO:0006869; P:lipid transport; IEA:Ensembl.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0090321; P:positive regulation of chylomicron remnant clearance; ISS:BHF-UCL.
DR   GO; GO:0051006; P:positive regulation of lipoprotein lipase activity; IMP:BHF-UCL.
DR   GO; GO:0017038; P:protein import; ISS:BHF-UCL.
DR   GO; GO:0034394; P:protein localization to cell surface; ISS:BHF-UCL.
DR   GO; GO:0050821; P:protein stabilization; ISS:BHF-UCL.
DR   GO; GO:0071503; P:response to heparin; IMP:BHF-UCL.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0045056; P:transcytosis; ISS:BHF-UCL.
DR   GO; GO:0070328; P:triglyceride homeostasis; IMP:BHF-UCL.
DR   InterPro; IPR016054; LY6_UPA_recep-like.
DR   Pfam; PF00021; UPAR_LY6; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disease mutation; Disulfide bond;
KW   Glycoprotein; GPI-anchor; HDL; Lipid-binding; Lipoprotein; Membrane;
KW   Polymorphism; Reference proteome; Signal; Transport.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    151       Glycosylphosphatidylinositol-anchored
FT                                high density lipoprotein-binding protein
FT                                1.
FT                                /FTId=PRO_0000318208.
FT   PROPEP      152    184       Removed in mature form. {ECO:0000305}.
FT                                /FTId=PRO_0000429858.
FT   DOMAIN       63    148       UPAR/Ly6.
FT   COMPBIAS     25     31       Poly-Glu.
FT   COMPBIAS     40     50       Poly-Glu.
FT   LIPID       151    151       GPI-anchor amidated glycine.
FT                                {ECO:0000305}.
FT   CARBOHYD     78     78       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     65     89       {ECO:0000250}.
FT   DISULFID     68     77       {ECO:0000250}.
FT   DISULFID     83    110       {ECO:0000250}.
FT   DISULFID    114    130       {ECO:0000250}.
FT   DISULFID    131    136       {ECO:0000250}.
FT   VARIANT      14     14       C -> F (polymorphism; it may act as a
FT                                disease modifier contributing to severe
FT                                HLPP1D when associated with R-68 or F-89;
FT                                results in decreased GPIHBP1 expression
FT                                at the cell surface; does not affect
FT                                interaction with LPL when associated in
FT                                cis with R-68 in one individual;
FT                                dbSNP:rs11538389).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:21816778,
FT                                ECO:0000269|PubMed:23831619}.
FT                                /FTId=VAR_044503.
FT   VARIANT      56     56       G -> R (polymorphism; no discernible
FT                                effect on interaction with LPL,
FT                                chylomicrons or APOA5;
FT                                dbSNP:rs587777636).
FT                                {ECO:0000269|PubMed:17883852,
FT                                ECO:0000269|PubMed:17997385}.
FT                                /FTId=VAR_044504.
FT   VARIANT      65     65       C -> S (in HLPP1D; does not affect
FT                                protein expression at the cell surface;
FT                                does not interact with LPL; promotes
FT                                formation of dimers and oligomers
FT                                severely reducing number of monomers;
FT                                dbSNP:rs587777638).
FT                                {ECO:0000269|PubMed:20026666,
FT                                ECO:0000269|PubMed:25387803}.
FT                                /FTId=VAR_071881.
FT   VARIANT      65     65       C -> Y (in HLPP1D; does not interact with
FT                                LPL; promotes formation of dimers and
FT                                oligomers severely reducing number of
FT                                monomers; dbSNP:rs587777638).
FT                                {ECO:0000269|PubMed:22239554,
FT                                ECO:0000269|PubMed:25387803}.
FT                                /FTId=VAR_077634.
FT   VARIANT      68     68       C -> G (in HLPP1D; does not affect
FT                                protein expression at the cell surface;
FT                                does not interact with LPL; promotes
FT                                formation of dimers and oligomers
FT                                reducing number of monomers;
FT                                dbSNP:rs587777639).
FT                                {ECO:0000269|PubMed:20026666,
FT                                ECO:0000269|PubMed:25387803}.
FT                                /FTId=VAR_071882.
FT   VARIANT      68     68       C -> R (in HLPP1D; unknown pathological
FT                                significance; results in decreased
FT                                GPIHBP1 expression; promotes formation of
FT                                dimers and oligomers severely reducing
FT                                number of monomers; does not affect
FT                                interaction with LPL when associated in
FT                                cis with F-14 in one individual).
FT                                {ECO:0000269|PubMed:23831619,
FT                                ECO:0000269|PubMed:25387803}.
FT                                /FTId=VAR_077635.
FT   VARIANT      68     68       C -> Y (in HLPP1D; does not interact with
FT                                LPL; promotes formation of dimers and
FT                                oligomers severely reducing number of
FT                                monomers). {ECO:0000269|PubMed:21314738,
FT                                ECO:0000269|PubMed:25387803}.
FT                                /FTId=VAR_077636.
FT   VARIANT      83     83       C -> R (in HLPP1D).
FT                                {ECO:0000269|PubMed:27578123}.
FT                                /FTId=VAR_077637.
FT   VARIANT      89     89       C -> F (in HLPP1D; drastically affects
FT                                interaction with LPL; promotes formation
FT                                of dimers and oligomers reducing number
FT                                of monomers; dbSNP:rs587777640).
FT                                {ECO:0000269|PubMed:21816778,
FT                                ECO:0000269|PubMed:25387803}.
FT                                /FTId=VAR_071883.
FT   VARIANT     108    108       T -> R (in HLPP1D; does not interact with
FT                                LPL; promotes formation of dimers and
FT                                oligomers reducing number of monomers).
FT                                {ECO:0000269|PubMed:22239554,
FT                                ECO:0000269|PubMed:25387803}.
FT                                /FTId=VAR_077638.
FT   VARIANT     115    115       Q -> P (in HLPP1D; a patient with
FT                                chylomicronemia; does not affect protein
FT                                expression at the cell surface; does not
FT                                interact with LPL; does not interact with
FT                                chylomicrons; promotes formation of
FT                                dimers and oligomers reducing number of
FT                                monomers; dbSNP:rs587777637).
FT                                {ECO:0000269|PubMed:19304573,
FT                                ECO:0000269|PubMed:22239554,
FT                                ECO:0000269|PubMed:25387803}.
FT                                /FTId=VAR_058086.
FT   VARIANT     144    144       S -> F (in HLPP1D; dbSNP:rs78367243).
FT                                {ECO:0000269|PubMed:22239554}.
FT                                /FTId=VAR_077639.
FT   VARIANT     175    175       G -> R (in HLPP1D; affects protein
FT                                expression at the cell surface; reduces
FT                                interaction with LPL; dbSNP:rs145844329).
FT                                {ECO:0000269|PubMed:21816778}.
FT                                /FTId=VAR_071884.
FT   MUTAGEN      66     66       Y->A: Promotes formation of dimers and
FT                                oligomers reducing number of monomers.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN      71     71       L->A: Promotes formation of dimers and
FT                                oligomers reducing number of monomers.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN      91     91       T->A: Promotes formation of dimers and
FT                                oligomers reducing number of monomers.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN      92     92       L->A: Only slightly increased formation
FT                                of dimers and oligomers. No effect on
FT                                number of monomers. Loss of LPL
FT                                interaction.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN      93     93       I->A: Promotes formation of dimers and
FT                                oligomers reducing number of monomers.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN     101    101       G->S: Promotes formation of dimers and
FT                                oligomers reducing number of monomers.
FT                                Retained some interaction with LPL.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN     104    104       T->A: Promotes formation of dimers and
FT                                oligomers reducing number of monomers.
FT                                Retained some interaction with LPL.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN     105    105       T->A: Promotes formation of dimers and
FT                                oligomers reducing number of monomers.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN     106    106       H->L: Promotes formation of dimers and
FT                                oligomers severely reducing number of
FT                                monomers. {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN     107    107       S->A: Promotes formation of dimers and
FT                                oligomers reducing number of monomers.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN     108    108       T->A: Retained some interaction with LPL.
FT                                No effect on number of monomers.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN     109    109       W->C,P,T: Promotes formation of dimers
FT                                and oligomers reducing number of
FT                                monomers. Loss of LPL interaction.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN     109    109       W->S,Y,H,A,F: Only slightly increased
FT                                formation of dimers and oligomers. No
FT                                effect on number of monomers. Loss of LPL
FT                                interaction.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN     115    115       Q->K: No effect on number of monomers.
FT                                {ECO:0000269|PubMed:25387803}.
FT   MUTAGEN     126    126       V->A: Promotes formation of dimers and
FT                                oligomers reducing number of monomers.
FT                                {ECO:0000269|PubMed:25387803}.
SQ   SEQUENCE   184 AA;  19806 MW;  89FF61B08A008C70 CRC64;
     MKALGAVLLA LLLCGRPGRG QTQQEEEEED EDHGPDDYDE EDEDEVEEEE TNRLPGGRSR
     VLLRCYTCKS LPRDERCNLT QNCSHGQTCT TLIAHGNTES GLLTTHSTWC TDSCQPITKT
     VEGTQVTMTC CQSSLCNVPP WQSSRVQDPT GKGAGGPRGS SETVGAALLL NLLAGLGAMG
     ARRP
//
